Compare Johnson & Johnson (JNJ) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs SpaceX — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 2.8× Johnson & Johnson's market cap, and Johnson & Johnson pays a 2.06% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| JNJ | SPCX | |
|---|---|---|
Market Cap | $626.09B | $1.76T |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $202.09 |
52-Week Low | $172.78 | $108.27 |
Enterprise Value | $654.37B | $1.70T |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
SPCX stock trades at $146.22, up 5.39% today, buoyed by strong technical momentum and positive news flow. The stock shows bullish moving average signals and trades above key support levels. Recent Q2 earnings beat expectations, though the company remains unprofitable with a net income margin of -35.66%. High-profile institutional investments, including Norway's sovereign wealth fund, underscore growing confidence in SpaceX's AI and Starlink growth trajectory.
Outlook is optimistic given analyst consensus and AI-driven revenue potential, but risks include persistent losses, high valuation multiples, and insider share unlocks. The consensus price target of $228.52 implies significant upside if execution aligns with ambitious growth plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
